Research.Patient.info
MSI-H/dMMR Gastroesophageal-junction Cancer research hub
2 indexed studies · 1 currently recruiting
- active not recruitingPHASE1, PHASE2
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
This study looks at a new drug, S095029, combined with an existing treatment, pembrolizumab, for advanced stomach or gastroesophageal junction cancer. It aims to check safety and how well it works for specific types of cancer that have particular genetic markers.
United States · Australia · Austria - recruitingPHASE2
Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
This study is testing new drug combinations for stomach and gullet cancer that have a specific genetic marker. It aims to see if these drugs can shrink tumours before surgery, potentially reducing the need for strong chemotherapy.
United Kingdom